{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T09:14:29Z","timestamp":1770714869178,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novartis Farma Italy"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40801-025-00514-w","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T12:00:58Z","timestamp":1760356858000},"page":"569-579","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Retention Rates of Biological Drugs in Spondyloarthritis: A 24-Month Observational Study in Patients Aged 60 Years or Older"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3074-4508","authenticated-orcid":false,"given":"Roberta","family":"Foti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2234-511X","authenticated-orcid":false,"given":"Francesco","family":"De Lucia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0349-7425","authenticated-orcid":false,"given":"Giorgio","family":"Amato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8213-5528","authenticated-orcid":false,"given":"Elisa","family":"Visalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7233-6369","authenticated-orcid":false,"given":"Ylenia","family":"Dal Bosco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5494-5179","authenticated-orcid":false,"given":"Fabio","family":"Aiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0613-0087","authenticated-orcid":false,"given":"Maria Gabriella","family":"Paol\u00ec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3272-4840","authenticated-orcid":false,"given":"Giambattista","family":"Privitera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6010-927X","authenticated-orcid":false,"given":"Angelo","family":"Montana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7301-8362","authenticated-orcid":false,"given":"Rosario","family":"Foti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"514_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11926-017-0633-0","volume":"19","author":"N Akkoc","year":"2017","unstructured":"Akkoc N, Can G, D\u2019Angelo S, Padula A, Olivieri I. Therapies of early, advanced, and late onset forms of axial spondyloarthritis, and the need for treat to target strategies. Curr Rheumatol Rep. 2017;19:8. https:\/\/doi.org\/10.1007\/s11926-017-0633-0.","journal-title":"Curr Rheumatol Rep"},{"key":"514_CR2","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/j.cgh.2018.12.032","volume":"17","author":"NZ Borren","year":"2019","unstructured":"Borren NZ, Ananthakrishnan AN. Safety of biologic therapy in older patients with immune-mediated diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17:1736-1743.e4. https:\/\/doi.org\/10.1016\/j.cgh.2018.12.032.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"514_CR3","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3899\/jrheum.210349","volume":"49","author":"GE Fragoulis","year":"2022","unstructured":"Fragoulis GE, Nikiphorou E, McInnes IB, Siebert S. Does age matter in Psoriatic arthritis? A narrative review. J Rheumatol. 2022;49:1085\u201391. https:\/\/doi.org\/10.3899\/jrheum.210349.","journal-title":"J Rheumatol"},{"key":"514_CR4","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/1756-185X.14092","volume":"24","author":"GRS Lim","year":"2021","unstructured":"Lim GRS, Ng CH, Kwan YH. Fong w prevalence and risk factors for falls in patients with spondyloarthritis: a systematic review. Int J Rheum Dis. 2021;24:623\u201332. https:\/\/doi.org\/10.1111\/1756-185X.14092.","journal-title":"Int J Rheum Dis"},{"key":"514_CR5","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s11926-013-0374-7","volume":"15","author":"I Olivieri","year":"2013","unstructured":"Olivieri I, D\u2019Angelo S, Padula A, Leccese P, Palazzi C. Spondyloarthritis with onset after age 45. Curr Rheumatol Rep. 2013;15:374. https:\/\/doi.org\/10.1007\/s11926-013-0374-7.","journal-title":"Curr Rheumatol Rep"},{"key":"514_CR6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s40266-015-0280-y","volume":"32","author":"\u00c9 Toussirot","year":"2015","unstructured":"Toussirot \u00c9. Diagnosis and management of late-onset spondyloarthritis: implications of treat-to-target recommendations. Drugs Aging. 2015;32:515\u201324. https:\/\/doi.org\/10.1007\/s40266-015-0280-y.","journal-title":"Drugs Aging"},{"key":"514_CR7","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1007\/s10067-022-06078-2","volume":"41","author":"F Ursini","year":"2022","unstructured":"Ursini F, Ruscitti P, Raimondo V, De Angelis R, Cacciapaglia F, Pigatto E, Olivo D, Di Cola I, Galluccio F, Francioso F, Foti R, Tavoni AG, D\u2019Angelo S, Campochiaro C, Motta F, De Santis M, Bilia S, Bruno C, De Luca G, Visentini M, Ciaffi J, Mancarella L, Brusi V, D\u2019Onghia M, Cuomo G, Fusaro E, Cipriani P, Dagna L, Guiducci S, Meliconi R, Iannone F, Iagnocco A, Giacomelli R, Ferri C. Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: a report of 30 cases. Clin Rheumatol. 2022;41:2261\u20137. https:\/\/doi.org\/10.1007\/s10067-022-06078-2.","journal-title":"Clin Rheumatol"},{"key":"514_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2022.105344","volume":"89","author":"D Wendling","year":"2022","unstructured":"Wendling D, Hecquet S, Fogel O, Letarouilly JG, Verhoeven F, Pham T, Prati C, Molto A, Goupille P, Dernis E, Saraux A, Ruyssen-Witrand A, Lukas C, Miceli-Richard C, Hudry C, Richette P, Breban M, Gossec L, Dougados M, Claudepierre P. 2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis. Jt Bone Spine. 2022;89: 105344. https:\/\/doi.org\/10.1016\/j.jbspin.2022.105344.","journal-title":"Jt Bone Spine"},{"key":"514_CR9","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1136\/ard.2005.035287","volume":"65","author":"R Fleischmann","year":"2006","unstructured":"Fleischmann R, Baumgartner SW, Weisman MH, Liu T, White B, Peloso P. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis. 2006;65:379\u201384. https:\/\/doi.org\/10.1136\/ard.2005.035287.","journal-title":"Ann Rheum Dis"},{"key":"514_CR10","doi-asserted-by":"publisher","DOI":"10.5402\/2011\/840475","volume":"2011","author":"I Hmamouchi","year":"2011","unstructured":"Hmamouchi I, Bahiri R, Hajjaj-Hassouni N. Clinical and radiological presentations of late-onset spondyloarthritis. ISRN Rheumatol. 2011;2011: 840475. https:\/\/doi.org\/10.5402\/2011\/840475.","journal-title":"ISRN Rheumatol"},{"key":"514_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-01132-6","volume":"11","author":"SH Kim","year":"2021","unstructured":"Kim SH, Kim HR, Lee SH, Shin K, Kim HA, Min HK. Effectiveness and drug retention of biologic disease modifying antirheumatic drugs in Korean patients with late onset ankylosing spondylitis. Sci Rep. 2021;11: 21555. https:\/\/doi.org\/10.1038\/s41598-021-01132-6.","journal-title":"Sci Rep"},{"key":"514_CR12","doi-asserted-by":"publisher","first-page":"1435599","DOI":"10.3389\/fimmu.2024.1435599","volume":"15","author":"R Ramonda","year":"2024","unstructured":"Ramonda R, Lorenzin M, Chimenti MS, D\u2019Angelo S, Marchesoni A, Selmi C, Lubrano E, Santo L, Luchetti Gentiloni MM, Atzeni F, Cauli A, Manara M, Rossini M, Foti R, Cozzi G, Scagnellato L, Ferraioli M, Carriero A, Luciano N, Ruzzon F, Fatica M, Fracassi E, Doria A, Foti R, Carletto A. Four-year real-world experience of secukinumab in a large Italian cohort of axial spondyloarthritis. Front Immunol. 2024;15:1435599. https:\/\/doi.org\/10.3389\/fimmu.2024.1435599.","journal-title":"Front Immunol"},{"key":"514_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejr.2024.10.001","volume":"47","author":"E Yilmaz","year":"2025","unstructured":"Yilmaz E, Toluk \u00d6. Clinical signficance of human leucocytic antigen (HLA-B27) in patients with early and late-onset axial spondyloarthritis. Egypt Rheumatol. 2025;47:12\u20135. https:\/\/doi.org\/10.1016\/j.ejr.2024.10.001.","journal-title":"Egypt Rheumatol"},{"key":"514_CR14","doi-asserted-by":"publisher","first-page":"491","DOI":"10.46497\/ArchRheumatol.2023.10580","volume":"38","author":"V Venerito","year":"2023","unstructured":"Venerito V, Del Vescovo S, Lopalco G, Proft F. Beyond the horizon: innovations and future directions in axial-spondyloarthritis. Arch Rheumatol. 2023;38:491\u2013511. https:\/\/doi.org\/10.46497\/ArchRheumatol.2023.10580.","journal-title":"Arch Rheumatol"},{"key":"514_CR15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jbspin.2014.10.012","volume":"82","author":"C Lahaye","year":"2015","unstructured":"Lahaye C, Tatar Z, Dubost JJ, Soubrier M. Overview of biologic treatments in the elderly. Jt Bone Spine. 2015;82:154\u201360. https:\/\/doi.org\/10.1016\/j.jbspin.2014.10.012.","journal-title":"Jt Bone Spine"},{"key":"514_CR16","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.semarthrit.2018.07.009","volume":"48","author":"DS Dalal","year":"2019","unstructured":"Dalal DS, Duran J, Brar T, Alqadi R, Halladay C, Lakhani A, Rudolph JL. Efficacy and safety of biological agents in the older rheumatoid arthritis patients compared to young: a systematic review and meta-analysis. Semin Arthritis Rheum. 2019;48:799\u2013807. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.07.009.","journal-title":"Semin Arthritis Rheum"},{"key":"514_CR17","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s40266-019-00688-3","volume":"36","author":"F Caso","year":"2019","unstructured":"Caso F, Tasso M, Chimenti MS, Navarini L, Perricone C, Girolimetto N, Peluso R, Del Puente A, Afeltra A, Perricone R, Punzi L, Scarpa R, Costa L. Late-onset and elderly psoriatic arthritis: clinical aspects and management. Drugs Aging. 2019;36:909\u201325. https:\/\/doi.org\/10.1007\/s40266-019-00688-3.","journal-title":"Drugs Aging"},{"key":"514_CR18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2165\/00002512-200724030-00005","volume":"24","author":"R Fleischmann","year":"2007","unstructured":"Fleischmann R, Iqbal I. Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. Drugs Aging. 2007;24:239\u201354. https:\/\/doi.org\/10.2165\/00002512-200724030-00005.","journal-title":"Drugs Aging"},{"key":"514_CR19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s40266-016-0374-1","volume":"33","author":"A Ishchenko","year":"2016","unstructured":"Ishchenko A, Lories RJ. Safety and efficacy of biological disease-modifying antirheumatic drugs in older rheumatoid arthritis patients: staying the distance. Drugs Aging. 2016;33:387\u201398. https:\/\/doi.org\/10.1007\/s40266-016-0374-1.","journal-title":"Drugs Aging"},{"key":"514_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13075-020-02231-x","volume":"22","author":"P Vela","year":"2020","unstructured":"Vela P, Sanchez-Piedra C, Perez-Garcia C, Castro-Villegas MC, Freire M, Mateo L, D\u00edaz-Torn\u00e9 C, Bohorquez C, Blanco-Madrigal JM, Ros-Vilamajo I, G\u00f3mez S, Ca\u00f1o R, S\u00e1nchez-Alonso F, D\u00edaz-Gonz\u00e1lez F, G\u00f3mez-Reino JJ. Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register. Arthritis Res Ther. 2020;22:143. https:\/\/doi.org\/10.1186\/s13075-020-02231-x.","journal-title":"Arthritis Res Ther"},{"key":"514_CR21","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1093\/rheumatology\/keac166","volume":"61","author":"M Bukhari","year":"2022","unstructured":"Bukhari M, Bergman M, Giles JT, Lozada C, Cush J, Yamaoka K, McKay C, Kavanaugh A. Safety of jakinibs: lessons from ORAL surveillance. Rheumatology (Oxford). 2022;61:4223\u20135. https:\/\/doi.org\/10.1093\/rheumatology\/keac166.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"514_CR22","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.exger.2006.10.010","volume":"41","author":"A Diaz-Borjon","year":"2006","unstructured":"Diaz-Borjon A, Weyand CM, Goronzy JJ. Treatment of chronic inflammatory diseases with biologic agents: opportunities and risks for the elderly. Exp Gerontol. 2006;41(12):1250\u20135. https:\/\/doi.org\/10.1016\/j.exger.2006.10.010.","journal-title":"Exp Gerontol"},{"key":"514_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.dld.2022.07.012","volume":"55","author":"L Guillo","year":"2023","unstructured":"Guillo L, Flachaire B, Avouac J, Dong C, Nachury M, Bouguen G, Buisson A, Caillo L, Fumery M, Gilletta C, H\u00e9buterne X, Lafforgue P, Laharie D, Mah\u00e9 E, Marotte H, Nancey S, Ottaviani S, Salmon JH, Savoye G, Serrero M, Uzzan M, Viguier M, Richez C, Peyrin-Biroulet L, Seksik P, Pham T, COMBIO Study Group. Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study. Dig Liver Dis. 2023;55:61\u20138. https:\/\/doi.org\/10.1016\/j.dld.2022.07.012.","journal-title":"Dig Liver Dis"},{"key":"514_CR24","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s40266-020-00801-x","volume":"37","author":"R Freitas","year":"2020","unstructured":"Freitas R, Godinho F, Madeira N, Fernandes BM, Costa F, Santiago M, Neto A, Azevedo S, Couto M, Sequeira G, Dias JM, Bernardes M, Miranda L, Pereira JP, Fonseca JE, Santos MJ. Safety and effectiveness of biologic disease-modifying antirheumatic drugs in older patients with rheumatoid arthritis: a prospective cohort study. Drugs Aging. 2020;37:899\u2013907. https:\/\/doi.org\/10.1007\/s40266-020-00801-x.","journal-title":"Drugs Aging"},{"issue":"Suppl 1","key":"514_CR25","doi-asserted-by":"publisher","first-page":"347.1","DOI":"10.1136\/annrheumdis-2024-eular.660","volume":"83","author":"J Brandt-Juergens","year":"2024","unstructured":"Brandt-Juergens J, Riechers E, Gente K, B\u00e4r S, Fliesser M, Peterlik D, Kiltz U. EULAR 2024 POS0199 How does age affect the safety profile in spondyloarthritis patients treated with secukinumab in real world? Data from the German AQUILA study. Ann Rheum Dis. 2024;83(Suppl 1):347.1-347. https:\/\/doi.org\/10.1136\/annrheumdis-2024-eular.660.","journal-title":"Ann Rheum Dis"},{"key":"514_CR26","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13075-024-03401-x","volume":"26","author":"R Ramonda","year":"2024","unstructured":"Ramonda R, Lorenzin M, Chimenti MS, Atzeni F, Semeraro A, D\u2019Angelo S, Selmi C, Ortolan A, Marchesoni A, Manara M, Luchetti Gentiloni MM, Santo L, Salvarani C, Cauli A, Rossini M, Amato G, Cozzi G, Scagnellato L, Ferraioli M, Carriero A, Fracassi E, Giorgio F, Doria A, Foti R, Carletto A, on behalf Spondyloarthritis and Psoriatic Arthritis SIR Study Group \u201cAntonio Spadaro.\u201d Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort. Arthritis Res Ther. 2024;26:172. https:\/\/doi.org\/10.1186\/s13075-024-03401-x.","journal-title":"Arthritis Res Ther"},{"key":"514_CR27","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1177\/039463200902200218","volume":"22","author":"A Migliore","year":"2009","unstructured":"Migliore A, Bizzi E, Lagan\u00e0 B, Altomonte L, Zaccari G, Granata M, Canzoni M, Marasini B, Massarotti M, Massafra U, Ranieri M, Pilla R, Martin LS, Pezza M, Vacca F, Galluccio A. The safety of anti-TNF agents in the elderly. Int J Immunopathol Pharmacol. 2009;22:415\u201326. https:\/\/doi.org\/10.1177\/039463200902200218.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"514_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1156557","volume":"10","author":"F Sivera","year":"2023","unstructured":"Sivera F, N\u00fa\u00f1ez-Monje V, Campos-Fern\u00e1ndez C, Balaguer-Trull I, Robustillo-Villarino M, Aguilar-Zamora M, Garijo-Bufort M, L\u00f3pez-G\u00f3mez JM, Pe\u00f1a-Gonz\u00e1lez C, de la Morena I, Bedoya-Sanch\u00eds D, Yankova-Komsalova L, Conesa-Mateos A, Mart\u00ednez-Crist\u00f3bal A, Navarro-Blasco FJ, Senabre-Gallego JM, Alegre-Sancho JJ. Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum. Front Med. 2023;10: 1156557. https:\/\/doi.org\/10.3389\/fmed.2023.1156557.","journal-title":"Front Med"},{"key":"514_CR29","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.55563\/clinexprheumatol\/znqm6v","volume":"40","author":"A Nallapati","year":"2022","unstructured":"Nallapati A, Wigley FM, Paik JJ. Improvement of salt and pepper skin changes in diffuse scleroderma after treatment with tofacitinib. Clin Exp Rheumatol. 2022;40:2008\u20139. https:\/\/doi.org\/10.55563\/clinexprheumatol\/znqm6v.","journal-title":"Clin Exp Rheumatol"},{"key":"514_CR30","doi-asserted-by":"publisher","first-page":"234","DOI":"10.2174\/1573397115666181130094455","volume":"15","author":"S Metyas","year":"2019","unstructured":"Metyas S, Tomassian C, Messiah R, Gettas T, Chen C, Quismorio A. Combination therapy of apremilast and biologic agent as a safe option of psoriatic arthritis and psoriasis. Curr Rheumatol Rev. 2019;15:234\u20137. https:\/\/doi.org\/10.2174\/1573397115666181130094455.","journal-title":"Curr Rheumatol Rev"},{"key":"514_CR31","doi-asserted-by":"publisher","first-page":"232","DOI":"10.46497\/ArchRheumatol.2024.10391","volume":"39","author":"S Uslu","year":"2024","unstructured":"Uslu S, G\u00fclle S, Urak \u00d6, \u015een G, Dalk\u0131l\u0131\u00e7 E, \u015eenel S, Akar S, \u0130nan\u00e7 N, Cefle A, K\u00f6ken Av\u015far A, Yolba\u015f S, Y\u0131lmaz S, Soysal G\u00fcnd\u00fcz \u00d6, Sar\u0131 \u0130, Birlik M, Akko\u00e7 N, \u00d6nen F. Biological treatment in elderly and young patients with ankylosing spondylitis: TURKBIO real-life data results. Arch Rheumatol. 2024;39:232\u201341. https:\/\/doi.org\/10.46497\/ArchRheumatol.2024.10391.","journal-title":"Arch Rheumatol"},{"key":"514_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1349533","volume":"11","author":"A Manfredi","year":"2024","unstructured":"Manfredi A, Fornaro M, Bazzani C, Perniola S, Cauli A, Rai A, Favalli EG, Bugatti S, Rossini M, Foti R, Conti F, Lopalco G, Scalvini A, Garufi C, Congia M, Gorla R, Gremese E, Atzeni F, Caporali R, Iannone F, Sebastiani M. Retention rate of biologic and targeted synthetic anti-rheumatic drugs in elderly rheumatoid arthritis patients: data from GISEA registry. Front Med Lausanne. 2024;11: 1349533. https:\/\/doi.org\/10.3389\/fmed.2024.1349533.","journal-title":"Front Med Lausanne"},{"key":"514_CR33","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2165\/11316350-000000000-00000","volume":"26","author":"S Tran","year":"2009","unstructured":"Tran S, Hooker RS, Cipher DJ, Reimold A. Patterns of biologic agent use in older males with inflammatory diseases: an institution-focused, observational post-marketing study. Drugs Aging. 2009;26:607\u201315. https:\/\/doi.org\/10.2165\/11316350-000000000-00000.","journal-title":"Drugs Aging"},{"key":"514_CR34","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/annrheumdis-2020-218808","volume":"80","author":"X Baraliakos","year":"2021","unstructured":"Baraliakos X, Gossec L, Pournara E, Jeka S, Mera-Varela A, D\u2019Angelo S, Schulz B, Rissler M, Nagar K, Perella C, Coates LC. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 maximise trial. Ann Rheum Dis. 2021;80:582\u201390. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218808.","journal-title":"Ann Rheum Dis"},{"key":"514_CR35","doi-asserted-by":"publisher","first-page":"e547","DOI":"10.1097\/RHU.0000000000001575","volume":"27","author":"JA Walsh","year":"2021","unstructured":"Walsh JA, Magrey M. Clinical manifestations and diagnosis of axial spondyloarthritis. J Clin Rheumatol. 2021;27:e547\u201360. https:\/\/doi.org\/10.1097\/RHU.0000000000001575.","journal-title":"J Clin Rheumatol"},{"issue":"10","key":"514_CR36","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1080\/14740338.2017.1361404","volume":"16","author":"G Murdaca","year":"2017","unstructured":"Murdaca G, Negrini S, Magnani O, Penza E, Pellecchio M, Puppo F. Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis. Expert Opin Drug Saf. 2017;16(10):1173\u20139. https:\/\/doi.org\/10.1080\/14740338.2017.1361404.","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"514_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11020433","volume":"11","author":"A Becciolini","year":"2023","unstructured":"Becciolini A, Parisi S, Del Medico P, Farina A, Visalli E, Molica Colella AB, Lumetti F, Caccavale R, Scolieri P, Andracco R, Girelli F, Bravi E, Colina M, Volpe A, Ianniello A, Ditto MC, Nucera V, Franchina V, Plat\u00e8 I, Donato ED, Amato G, Salvarani C, Bernardi S, Lucchini G, De Lucia F, Molica Colella F, Santilli D, Mansueto N, Ferrero G, Marchetta A, Arrigoni E, Foti R, Sandri G, Bruzzese V, Paroli M, Fusaro E, Ariani A. Predictors of DAPSA response in psoriatic arthritis patients treated with apremilast in a retrospective observational multi-centric study. Biomedicines. 2023;11(2): 433. https:\/\/doi.org\/10.3390\/biomedicines11020433.","journal-title":"Biomedicines"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-025-00514-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-025-00514-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-025-00514-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T01:17:06Z","timestamp":1763687826000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-025-00514-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["514"],"URL":"https:\/\/doi.org\/10.1007\/s40801-025-00514-w","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"10 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Roberta Foti, Francesco De Lucia, Giorgio Amato, Elisa Visalli, Ylenia Dal Bosco, Fabio Aiello, Maria Gabriella Paol\u00ec, Giambattista Privitera, Angelo Montana declare no conflicts of interest. Rosario Foti received financial support from Abbvie, Alfa-Wasserman, Amgen, Bms, Celgene, Galapagos, Italfarmaco, Janssen, Msd, Eli-Lilly, Novartis, Pfizer, Ucb and Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Study design: Roberta Foti, Rosario Foti, Francesco De Lucia; data collection and interpretation: all authors; manuscript writing: Roberta Foti, Francesco De Lucia, Rosario Foti; manuscript editing: all authors; approval to submit: all authors. All authors read and approved the final version.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Editorial assistance was supported by Novartis Farma Italy.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The data presented in this study are available upon reasonable request from the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"All patients provided signed informed consent to participate in this study.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Ethics approval was obtained by the ethics committee of AOU Policlinico CT (approval no. 16019). All procedures performed were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}